A new weapon against an old target
- PMID: 21861856
- PMCID: PMC3239345
- DOI: 10.1186/ar3392
A new weapon against an old target
Abstract
High expression of folate receptors is characteristic for the effector cell population of synovial macrophages in synovial inflammation. A new drug conjugate, EC0746, targets the folate inhibitor aminopterin to folate receptors. In vitro studies show that this conjugate acts antiproliferatively and inhibits cytokine production by macrophage cell lines. Moreover, it shows strong anti-arthritic effects in the rat model of adjuvant-induced arthritis in vivo. Toxicity of aminopterin was reduced 40-fold by using equimolar doses of the drug conjugate. In conclusion, this new treatment approach has the potential to further improve the most successful principle of folate inhibition in the treatment of arthritis.
Comment on
-
Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.Arthritis Res Ther. 2011 Apr 4;13(2):R56. doi: 10.1186/ar3304. Arthritis Res Ther. 2011. PMID: 21463515 Free PMC article.
References
-
- Fiehn C. Methotrexate transport mechanisms: the basis for targeted drug delivery and β-folate-receptor-specific treatment. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S40–45. - PubMed
-
- Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Tsukano M, Ratnam M, Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:1609–1616. doi: 10.1002/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical